Hinchcliff EM - Search Results

1

Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.

Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Hinchcliff EM, et al. Cancer. 2024 Apr 1;130(7):1061-1071. doi: 10.1002/cncr.35126. Epub 2023 Nov 27. Cancer. 2024. PMID: 38009662 Clinical Trial.

2

Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies.

Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL. Hinchcliff E, et al. Int J Gynecol Cancer. 2019 May 22:ijgc-2019-000499. doi: 10.1136/ijgc-2019-000499. Online ahead of print. Int J Gynecol Cancer. 2019. PMID: 31118216 Free PMC article.

3

Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.

Sakellariou-Thompson D, Forget MA, Hinchcliff E, Celestino J, Hwu P, Jazaeri AA, Haymaker C, Bernatchez C. Sakellariou-Thompson D, et al. Cancer Immunol Immunother. 2019 Nov;68(11):1747-1757. doi: 10.1007/s00262-019-02402-z. Epub 2019 Oct 10. Cancer Immunol Immunother. 2019. PMID: 31602489 Free PMC article.

4

Sunset, or dawn of a new age for ovarian cancer vaccine therapy?

Hinchcliff E, Jazaeri AA. Hinchcliff E, et al. Gynecol Oncol. 2019 Dec;155(3):387-388. doi: 10.1016/j.ygyno.2019.11.011. Gynecol Oncol. 2019. PMID: 31812214 No abstract available.

5

The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.

Pham MM, Hinchcliff E, Avila M, Westin SN. Pham MM, et al. Cancer J. 2021 Nov-Dec 01;27(6):491-500. doi: 10.1097/PPO.0000000000000562. Cancer J. 2021. PMID: 34904812 Free PMC article. Review.

6

Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma.

Hinchcliff E, Rumpf J, Ratan R, Fleming ND, Jazaeri A, Fellman B, Meyer L, Soliman P. Hinchcliff E, et al. Gynecol Oncol. 2022 Dec;167(3):490-495. doi: 10.1016/j.ygyno.2022.09.024. Epub 2022 Oct 19. Gynecol Oncol. 2022. PMID: 36270831

7

Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer.

Pham MM, Avila M, Hinchcliff E, Westin SN. Pham MM, et al. Cancer Treat Res. 2023;186:71-89. doi: 10.1007/978-3-031-30065-3_5. Cancer Treat Res. 2023. PMID: 37978131

8

State of the science: Contemporary front-line treatment of advanced ovarian cancer.

Hinchcliff E, Westin SN, Herzog TJ. Hinchcliff E, et al. Gynecol Oncol. 2022 Jul;166(1):18-24. doi: 10.1016/j.ygyno.2022.04.021. Epub 2022 May 17. Gynecol Oncol. 2022. PMID: 35589433 No abstract available.

9

A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.

Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. Jazaeri A, et al. Among authors: hinchcliff em. Gynecol Oncol. 2018 Nov;151(2):374-380. doi: 10.1016/j.ygyno.2018.08.037. Epub 2018 Sep 10. Gynecol Oncol. 2018. PMID: 30213435 Free PMC article. Review.

10

Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.

Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Hinchcliff E, et al. Gynecol Oncol. 2018 Dec;151(3):407-413. doi: 10.1016/j.ygyno.2018.10.008. Epub 2018 Oct 24. Gynecol Oncol. 2018. PMID: 30366646 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page